cannabis
Smart Inhaler vs Cheap Vaporizer 3 Cannabis Benefits In 2025, the Chronic Pain Registry found that patients who used low-cost vaporizers saved 38% on out-of-pocket expenses while achieving the same pain relief as those using smart inhalers. The data span 12,000 chronic-pain users across 15 states and compare device
cannabis
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. When a single headline claims “rapid relief for chronic pain,” is it science or spin? In short, the promise mixes genuine therapeutic signals with marketing
cannabis
In 2023, a head-to-head trial reported that rapid-release cannabis topicals reduced pain scores by 36% compared with NSAID gels, making them the more effective option for arthritis relief. These fast-acting creams have become a focal point for seniors seeking alternatives to oral pain medicines. I have followed the rollout of
cannabis
In 2026, a randomized study found hemp oil cut recovery time about 30% more than whey protein shakes, showing a clear edge for post-workout regeneration. The research compared elite runners who took cannabis-derived hemp oil before training with those who used traditional whey, measuring glycogen refill, inflammation and performance metrics.
cannabis
18% of Curaleaf pre-rolled users reported measurable symptom improvement, according to the February 2026 lawsuit, which claims the brand overstated its pain-relief benefits. The case highlights how unverified health claims can mislead shoppers seeking relief. Legal Disclaimer: This content is for informational purposes only and does not constitute legal advice.
cannabis
2025 marked a turning point as federal actions forced Curaleaf and Aurora Cannabis to reassess their touted health benefits. Both firms claim comparable therapeutic outcomes, yet recent penalties and regulatory scrutiny expose gaps that could reshape investor confidence. Legal Disclaimer: This content is for informational purposes only and does not
cannabis
7 Cannabis Benefits vs Opioid Pain Finally Makes Sense 23 percent of former opioid users reported better sleep after switching to cannabis, according to the 2025 National Health Interview Survey. Cannabis provides multiple benefits for chronic pain that can replace opioids, including reduced pain intensity, lower inflammation, and improved quality
cannabis
The real verdict is that roughly 60% of newer strain names are marketing buzzwords, not scientific descriptors. This confusion inflates prices while obscuring the plant’s genuine therapeutic potential. Strain Naming: The Marketing Mirage When I first started cataloging hundreds of cultivars for a research database, I noticed a pattern:
cannabis
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Hook Curaleaf's health claims are not fully proven; many rely on preliminary data rather than robust clinical trials. In 2024, Curaleaf reported $1.
cannabis
Cannabis Benefits Vs False Claims Regulatory Shock In 2025, a $25 million settlement sparked the biggest regulatory shock in the cannabis sector, forcing big-name retailers to re-evaluate health-claim messaging and putting consumers at risk. The lawsuit targets unverified wellness promises that have flooded product labels for years. As regulators tighten
cannabis
Half of all cannabis licenses are linked to compliance gaps uncovered by the FBI’s 2026 probe, according to a DOJ-released summary. The investigation found that 50% of licensed operators showed irregular financial reporting, raising red flags for regulators. Legal Disclaimer: This content is for informational purposes only and does
cannabis
3 Hidden Costs Lurking in Cannabis Benefits Claims In 2026, Curaleaf's stock experienced a three-day swing after a whistleblower alleged misrepresentation of cannabis benefits. The rapid rise and fall raised questions about how quickly the market reacts to benefit claims that may not hold up under scrutiny. I